Medical Portal. Disease, Symptoms, Treatment
Home ยป Interactive ยป Ciprofloxacin "Fresenius Kabi"

Ciprofloxacin "Fresenius Kabi"


Producer: Fresenius Kabi

contains

Ciprofloxacin "Fresenius Kabi" is an antibiotic. Fluoroquinolone.

Active substances

ciprofloxacin


Application

Ciprofloxacin "Fresenius Kabi" is used for:

  • Treatment of serious infections with bacteria that may be affected by ciprofloxacin, eg:
    • complicated urinary tract infections
    • blood poisoning
    • typhoid
    • paratyphoid
    • Legionella
    • other rare infections
    • pneumonia's people with cystic fibrosis.
  • Prevention modmeningitis caused by meningococcal bacteria.

Dosage

Available as a solution for infusion into a vein.

infections

  • 200-400 mg twice a day.

Acute pneumonia by cystic fibrosis

  • Children over 5 years. Usually 10 mg per kg body weight 3 times a day. no more than 1,200 mg per day.

Complicated urinary tract infections

  • Children. 6-10 mg per kg body weight every 8 hours, maximum 400 mg per dosage.

Note: Reduced dose in poorly functioning kidneys.


possible side effects

Common (1-10%)

Diarrhea, Nausea

Uncommon (0.1-1%)

Abdominal pains

Joint pain

Hyperactivity, Dizziness, Unrest and Restlessness

Infection with resistant fungi

Impact of the kidneys

Rare (0.01-0.1%)

Poor functioning liver, hepatitis, colonitis

Swelling due to fluid accumulation in the body, low blood pressure, shortness of breath

Anemia, Increased risk of infections due. Lack of white blood cells, increased tendency for blood clots due. Elevated platelet count, increased bleeding tendency due. Decrease in the number of platelets

High blood sugar, low blood sugar

arthritis

Anxiety, Syncope, Depression *, confusion, hallucinations, seizures, decreased sensation, tremor, change in the skin's sense of touch, increased muscle tension

Hypersensitivity to sunlight

Allergic swelling of the face as well as the oral cavity and larynx, Allergic reactions

Inflammation of the kidneys, blood in the urine, kidney failure

Hearing loss, vision disturbances **, tinnitus

Very rare (less than 0.01%)

Inflammation of the pancreas, destruction of the liver cells ***

Inflammation of blood vessels

Blood deficiency and increased risk of infection due to lack of white blood cells, Impact of bone marrow production of blood cells

Worsening of the very rare muscle disease myasthenia gravis, muscle weakness, tendon damage

Coronary heart disease, Coordination disorder, Migraine, Psychosis *, Increased pressure in the brain, Increased pressure in the skull

Serious skin reaction, Severe skin reaction where skin is damaged, Skin bleeding and mucous membranes

Anaphylactic shock - An acute severe allergic condition, rash and fever and pain and swelling of joints

Unknown

Heart Bank, Cardiac arrhythmias, Impact of ekg

Increased bleeding tendency

Slight increase in mood, ways, nerve inflammation, eg on the arms and legs

Severe drug reaction with internal organs

* Possibly. with suicide thoughts or suicide behaviors.

** Impact of the vision involves the risk of net prevention.

*** Rarely develops into life-threatening liver failure.

  • Already within the first 48 hours after treatment initiation, tendonitis and late lesions (especially acute tendon) may occur.
  • Inflammation and damage to the tendons may occur even several months after treatment with Ciprofloxacin "Fresenius Kabi".
  • The risk of inflammation of tendons is higher in elderly patients and in patients who are treated with adrenal gland hormones at the same time.
  • Treatment provides a risk of infection with resistance bacteria and fungi.

Should not be used

Ciprofloxacin "Fresenius Kabi" should not be used

  • For children and adolescents who are still growing, as there is a theoretical risk of damage to joints. However, may be used for children as a single dose for prevention of depression and for children with cystic fibrosis.
  • If you have had late diseases associated with treatment with fluoroquinolones (one type of antibiotics).

Pregnancy

Use only under certain conditions. This text differs from the company's approved product information (product summary). May be used only under certain conditions. This text differs from the company's approved product information (product summary).

The drug can be used briefly during the first 3 months of pregnancy, as agreed with the doctor.


breastfeeding

Can be used if necessary. This text differs from the company's approved product information (product summary).

Traffic

No warning.

Blood donor

Do not drop. 4 weeks quarantine after end of treatment.

doping

Injection of more than 100 ml of infusion into a vein within 12 hours is prohibited with the exception of legally received treatment in hospital or medical examinations.


effect

  • Works by inhibiting enzyme synthesis in the bacteria so that they go to the ground.
  • The agent is effective against many different bacterial species and is thus broad-spectrum.
  • The half life in the blood (T?) is 3-5 hours.

Pharmaceutical forms

Solution for infusion. 1 ml contains 2 mg ciprofloxacin (as hydrogen sulphate).


Special warnings

Ciprofloxacin "Fresenius Kabi" should be used with caution:

  • In any treatment with an antibiotic, the bacteria may become insensitive (resistant) to the used agent and any other antibiotics. Ciprofloxacin "Fresenius Kabi" is broad-spectrum, and the risk of development of resistance is therefore greater than with ordinary penicillin.
  • The absorption of Ciprofloxacin "Fresenius Kabi" in the body is inhibited if taken concurrently with dairy products. Ciprofloxacin "Fresenius Kabi" should therefore be taken at least 3 hours before or after ingestion of milk products.
  • Ciprofloxacin "Fresenius Kabi" may reduce the seizure threshold and should therefore be used with great caution for epilepsy or tension.
  • As individuals develop light eczema, strong sunlight and solarium should be avoided.
  • In the very rare muscle disease myasthenia gravis.
  • Contact immediately:
    • Eye doctor if you experience vision impairment or other eye effects.
    • Your doctor, if you notice signs of nerve inflammation or other painful inflammation, pain, burning sensation, dizziness and numbness, numbness and / or weakness so that your doctor can assess whether treatment should continue.
  • sodium 100 ml (200 mg) contains sodium equivalent to 0.9 g sodium chloride. If you are on sodium or low fat diet, take into account the sodium content.

Using other medicines

It is important to inform your doctor about all the medicines you are taking.
  • Ciprofloxacin "Fresenius Kabi" must not be taken with tizanidine (muscle relaxant).
  • Ciprofloxacin "Fresenius Kabi" may increase the effect of theophylline (asthma agent), methotrexate (rheumatoid arthritis) and zolpidem (sleeper).
  • Ciprofloxacin "Fresenius Kabi" has in some cases increased the effect of glibenclamide (antidiabetic agent).
  • The dose of the following agents should be altered when co-administered Ciprofloxacin "Fresenius Kabi":
    • diclofenac (anti-rheumatoid arthritis and pain)
    • methotrexate (rheumatoid arthritis)
    • ropivacaine (local anesthetic)
    • sildenafil (anti-impotence or excessive blood pressure in the lungs)
    • theophylline (asthma agent)
    • warfarin (anticoagulant).
  • Sucralfat (antidiabetic agent) reduces the effect of Ciprofloxacin "Fresenius Kabi" and therefore sucralfat should be taken at least 6 hours before Ciprofloxacin "Fresenius Kabi".

Grants, delivery, packages and prices

subsidiesextraditionDispensing form and strengthPackingPrice in kr.
May only be delivered once after the same prescription unless the recipient has stated on the prescription, how many times and with what time intervals additional extradition must take placesolution for infusion2 mg / ml10 x 100 mL (KabiPac)152,75
May only be delivered once after the same prescription unless the recipient has stated on the prescription, how many times and with what time intervals additional extradition must take placesolution for infusion2 mg / ml10 x 200 ml (KabiPac)194,30



Ciprofloxacin

FAQ - 💬

👉 Fresenius Kabi Nederland B.V. submitted applications for mutual recognition of Ciprofloxacine Kabi and associated names, Solution for infusion, 2 mg/ml on the basis of the marketing authorisation granted by Netherlands on 23 September 2005. The Mutual Recognition Procedure started on 17 December 2005.

👉 Ciprofloxacine Kabi and associated names, Solution for infusion, 2 mg/ml, is an antibiotic belonging to the quinolone family effective in vitro against a large number of Gram-negative aerobic bacteria as well as against some Gram-positive organisms.

👉 At Fresenius Kabi, we have a singular purpose โ€“ to put lifesaving medicines and technologies in the hands of healthcare professionals and to find answers to the challenges they face. Never has this purpose been more important, as the world faces an unprecedented threat from a virus we have not seen before.


If You Liked Our Article And You, Have Something To Add, Share Your Thoughts. It Is Very Important To Know Your Opinion!

Add A Comment